Members of the World Health Organization (WHO) have agreed to recite the legally binding treaty designed to deal with future epidemic better.

The treaty is to avoid chaos and competition for resources seen during the outbreak of Kovid -19.

Major elements include rapid sharing of data about new diseases, to ensure that scientists and pharmaceutical companies can work more rapidly to develop treatment and vaccines.

For the first time, the WHO will also observe the global supply chains for the self -mask, medical gowns and other individual safety equipment (PPE).

WHO Director General Dr. Tedros Adnom Gabrisus described the deal as “an important milestone in our shared journey towards a safe world”.

“(Member states) have also demonstrated that multilateralism is alive and well, and in our divided world, nations can still work together to find common land, and a shared response to shared threats,” he said.

In early Wednesday, the legally binding agreement came after a three -year conversation between the member states.

This is the second time in the 75-year history of WHO that an international agreement of this type is-the first tobacco control deal in 2003.

It should still be formally adopted by members when it is found for the World Health Assembly next month.

American negotiaters were not part of final discussions after President Donald Trump announced his decision to withdraw his decision to withdraw from the global health agency, and would not be bound by the US Treaty when departed in 2026.

Under the agreed conditions, countries must ensure that future outbreaks are available around the world.

The participating manufacturers must allocate 20% of their production of vaccines, medical science and diagnosis to WHO. Donation will have to be donated with the rest supplied at at least 10% cheaper prices.

Countries also approved the transfer of health technologies to poor countries, until it was “mutually agreed”.

It should also enable more local production of vaccines and drugs during an epidemic. But that section was very controversial.

Developing countries are still angry at rich countries and rough vaccines during Covid-19, while the concerns of countries with large pharmaceutical industries can essentially weaken research and development.

The root of the agreement has a proposed pathogen access and profit-sharing system (PABS), allowing rapid exchange of data between pharmaceutical companies.

With this, those firms should be able to start working on new drugs in any future outbreak.